The Chemours Company (CC) Q4 2025 earnings summary

Executive summary

• Achieved strong free cash flow of $92 million in Q4 2025, with full year net sales of $5.8 billion and adjusted EBITDA of $742 million; TSS segment delivered record Opteon™ Refrigerants growth, up 37% in Q4 and 56% for the year, while TT and APM faced volume declines due to weaker end markets.

• Announced sale of Kuan Yin TiO2 site for approximately $300 million in net proceeds to reduce debt and support deleveraging.

• Implemented cost-saving and operational excellence initiatives, delivering $125 million in gross controllable cost savings in 2025.

• Advanced Pathway to Thrive strategy, focusing on operational excellence, growth, and portfolio management.

• Q4 2025 net loss was $47 million, mainly due to lower production, non-cash inventory charges, and higher taxes; full year net loss was $386 million, primarily from litigation-related charges.

Financial highlights

• Q4 2025 net sales were $1.3 billion, with adjusted EBITDA of $128 million; full year net sales were $5.8 billion and adjusted EBITDA $742 million.

• Q4 2025 free cash flow was $92 million (72% conversion), up from $29 million in Q4 2024; full year free cash flow was $51 million, a $1,044 million improvement year-over-year.

• Adjusted EBITDA margin for TSS was 29% in Q4 2025 and 32% for the full year; TT and APM margins were 4% each in Q4.

• Corporate expenses and capital expenditures decreased year-over-year, reflecting ongoing cost management.

• Net leverage ratio at year-end 2025 was 4.7x, with net debt of $3.5 billion and liquidity of $1.6 billion.

Outlook and guidance

• 2026 net sales growth expected at 3–5%, with adjusted EBITDA projected at $800–$900 million and free cash flow conversion above 25%.

• Q1 2026 consolidated net sales expected to rise 3–5% sequentially; adjusted EBITDA forecasted at $120–$150 million.

• TSS Q1 2026 net sales projected to increase 20–30% sequentially, led by Opteon™ Refrigerants; TT and APM expected to see sequential declines.

• Capital expenditures for 2026 anticipated at $275–$325 million.

• Net leverage ratio targeted below 4x by end of 2026, progressing toward a long-term goal of below 3x.